Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DynPort Vaccine Company, a unit of Computer Sciences Corporation, has entered into a phase II clinical trial for its recombinant plague vaccine candidate, rF1V.
Subscribe to our email newsletter
The phase II trial will test different vaccine dosages and schedules in 400 healthy volunteers between the ages of 18 and 55. The clinical trial is underway and will continue into 2007 at eight locations across the US.
“Plague has been identified as a category A bioterrorism agent by the Centers for Disease Control and Prevention. The candidate’s entry into a phase II trial is a significant step toward DVC’s goal of a licensed plague vaccine,” said Dr Robert House, president and chief scientific officer of DynPort Vaccine Company (DVC).
The plague vaccine candidate, which is designed to provide protection against the plague bacterium Yersinia pestis, was originally identified and developed by scientists working at the US Army Medical Research Institute of Infectious Diseases (USAMRIID).
Their work involved the identification of suitable protein antigens and the development of the processes used to assess the performance of the vaccine. Further development and manufacture of the vaccine candidate has been achieved by DVC under a contract with the Department of Defense.